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Objective: This study was undertaken to determine the cost per quality-adjusted
life-year gained with lung transplantation relative to medical treatment for end-
stage lung disease in the United Kingdom.
Methods: Patients on the transplant waiting list were used to represent medical
treatment. Four-year national survival data were extrapolated to 15 years by means
of parametric techniques. Quality-adjusted life-years were derived by means of util-
ity scores obtained from a cross-section of patients. Resource consumption and
costs were based on local and national sources. Costs and benefits were discounted
at an annual rate of 6%.
Results: Across a 15-year period lung transplantation yielded mean benefits (rela-
tive to medical treatment) of 2.1, 3.3, and 3.6 quality-adjusted life-years for single-
lung, double-lung, and heart-lung transplantation, respectively. During the same
period the mean cost of medical treatment was estimated at $73,564, compared with
$176,640, $180,528, and $178,387 for single-lung, double-lung, and heart-lung
transplantation, respectively. The costs per quality-adjusted life-year gained were
$48,241 for single-lung, $32,803 for double-lung, and $29,285 for heart-lung
transplantation. Sensitivity analysis found the principal determinants of cost-
effectiveness to be quality of life and maintenance costs after transplantation.
Conclusions: Lung transplantation results in survival and quality of life gains but
remains expensive, with cost-effectiveness limited by substantial mortality and
morbidity and high costs. The cost-effectiveness of lung transplantation can be
improved with lowered immunosuppression costs and improvements in quality of
life after transplantation.
Assessing the benefits of any transplanted organ is problematic.Because the introduction of transplantation was not preceded byclinical trials, there are no true control groups. Most of the evi-dence on which the benefits of transplantation are based is rela-tively soft and can still be questioned.1,2 Additionally, variousfactors limit the reliability of data on costs associated with organ
transplantation.3 The paucity of hard data on costs and benefits means that few eco-
nomic data are available for lung transplantation. Ramsey and colleagues4 from
Washington, DC, published a pilot study on cost-effectiveness of lung transplanta-
tion but stressed the need for a prospective multicenter study. The Dutch Medical
Technology Assessment Team5 followed up with a detailed prospective economic
evaluation of the Dutch lung transplant program, but their study was also a single-
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center analysis with small numbers. Our article describes a
larger study incorporating data from seven transplantation
units. The objectives of our study were to ascertain the
costs, benefits, and cost-effectiveness of lung transplanta-
tion in the United Kingdom relative to medical treatment
for end-stage lung disease.
Methods
Study Design and Definition of Treatment Groups
This analysis was a cost-utility study that was based on lung trans-
plantation practice in the United Kingdom. The analysis compared
the three main forms of lung transplantation—single-lung, double-
lung (including bilateral single-lung transplantation), and heart-
lung transplantation—with medical treatment for end-stage lung
disease. The perspective for all analysis and discussion in this work
was societal; costs accrued by all health care sectors, not just those
borne by the transplanting unit, were considered.
Survival Data
Data from the UK Cardiothoracic Transplant Audit, a national
database of transplantation in the United Kingdom,6 was used to
compute survivals. Comparisons between transplantation and
medical treatment were made with methods similar to those
described by the Dutch group.5,7-9 Patients on the organ waiting
list were used as a proxy for control patients without transplanta-
tion (medical treatment). These patients contributed to the analy-
sis only as long as they remained on the waiting list. Data from
patients who underwent transplantation or were removed from the
waiting list were censored at time of transplantation or removal.
Patients on the waiting list were assumed to be a single group,
regardless of diagnosis and type of transplant required.
Survival was based on transplantation and waiting-list activity
in the United Kingdom from April 1995 through March 1999, with
follow-up till June 2000.
Utility Data
Utility scores were obtained from a parallel study of health-related
quality of life in lung transplantation.10 In that study we measured
health utility in a cross-section of transplant recipients with the
EuroQol method.11,12 Utility was measured on a scale of 0 to 1.
Cost Data
The main costs of transplantation fall into four categories: pretrans-
plantation costs (including transplant assessment and medical care
while on the waiting list), donor screening and acquisition, trans-
plant procedure, and long-term follow-up and maintenance. Sources
of resource consumption were identified in each category, and costs
were assigned in a disaggregated form (costs were figured sepa-
rately for events and then total cost was derived). The unit con-
sumptions for principal events such as intensive treatment unit stay,
hospital stay, reoperations, intra-aortic balloon pump use, rejection
episodes, and infection episodes were obtained from prospectively
recorded data held by the UK Cardiothoracic Transplant Audit
between 1995 and 2000. Several sources, published and unpub-
lished, were used to obtain cost data. These included peer-reviewed
literature, accounts departments in transplantation units, the
Department of Health, the regional transplant coordinator’s office,
and cost data from various health authorities. Best available data
were used, with reliance on published or directly measured data
wherever possible. Standardized costs for emergency operating the-
ater time, intensive care bed-days, and hospital bed-days were
weighted by a factor of 1.3 on the presumption that transplantation
is more resource intensive than other types of major surgery.
Follow-up costs were based on a model developed by the Papworth
unit for modeling posttransplantation costs.13
Costs accrued before transplantation and in the first posttrans-
plantation week were assigned to all transplant recipients.
Transplant recipients were assumed to have undergone a year of
medical treatment before transplantation (on the basis of current
median waiting time for lung transplantation in the United
Kingdom). The average costs were calculated for the first week
then thereafter at increasing intervals to 2 years, after which costs
were calculated on a yearly basis. The follow-up costs were based
on the proportion of patients surviving to the beginning of a given
interval, because costs can only be accrued by patients alive in the
given interval. The average cost of an event per transplant recipi-
ent for each interval was calculated as follows: cost of event per
recipient = proportion of recipients alive at beginning of interval ×
average cost of event per month for live patient × proportion of
survivors experiencing event × interval in months.
Costs beyond 4 years were based on extrapolation of the fourth
year’s data, allowing for an increasing incidence of obliterative
bronchiolitis during 10 years in the transplantation group. It was
assumed that the hazard rates for rejection and infection between
36 and 48 months would remain constant in subsequent years.
Costs were computed in 1999 UK pounds sterling (converted
to US dollars at the average 1999 rate of £1/$1.64).
Modeling of Cost-Utility
The cost-utility was modeled across a 15-year period. Costs and
benefits were discounted at a rate of 6%. The incremental costs or
benefits for single-lung, heart-lung, and double-lung transplanta-
tion were calculated as the summation of the differences between
the costs or benefits of the respective transplantation group and the
medical care group for each time interval. To obtain the quality-
adjusted survival, the survival for each interval was multiplied by
the utility tariff for that period. The total life-years and
quality–adjusted life-years (QALY) gained per procedure could
thus be determined by calculating the difference in area under the
survival curves. Finally, the cost per life-year or QALY gained was
determined by dividing the incremental cost by the incremental
benefit of each procedure. Sensitivity analyses were performed to
determine the influence of key assumptions.
Statistical Analysis
Data were analyzed with SAS statistical software version 6.12
(SAS Institute, Inc, Cary, NC) for statistical analysis and with
Microsoft Excel version 97 (Microsoft Corporation, Redmond,
Wash) for spreadsheet-based calculations. Survival analysis was
performed with the Kaplan-Meier method, with extrapolation
beyond 4 years according to the Weibull method. It was, however,
thought unlikely that patients with end-stage lung disease would
survive more than 10 years after listing, so all patients in the med-
Anyanwu et al Cardiothoracic Transplantation
The Journal of Thoracic and Cardiovascular Surgery • Volume 123, Number 3   413
TX
ET
CS
P
A
CD
TX
G
TS
ED
IT
O
RI
A
L
ical treatment arm were assumed to be dead by the end of the 10th
year. Day zero for the waiting list analysis was the time of place-
ment on the waiting list.
Results
Benefits
Observed survivals with and without transplantation from
a 4-year cohort of UK patients (1030 on waiting list and
260 single-lung, 199 double-lung, and 218 heart-lung
TABLE 1. Survivals with and without transplantation
1 y 3 y 4 y 10 y 15 y
Waiting list
Kaplan-Meier (observed) 66% 39% 29% — —
Weibull (extrapolated) 67% 37% 29% 5% 0%
Single-lung transplantation
Kaplan-Meier (observed) 72% 55% 43% — —
Weibull (extrapolated) 71% 55% 49% 31% 24%
Double-lung transplantation
Kaplan-Meier (observed) 69% 59% 51% — —
Weibull (extrapolated) 69% 55% 51% 37% 30%
Heart-lung transplantation
Kaplan-Meier (observed) 69% 57% 54% — —
Weibull (extrapolated) 71% 57% 53% 41% 34%
Figure 1. Survival difference between medical treatment and transplantation calculated as difference in area under
curve at discount rate of 6%. Solid rule, Medical treatment; short dashes, single-lung transplantation (2.0 life-years
gained); long dashes, double-lung transplantation (2.4 life-years gained); alternating short and long dashes, heart-
lung transplantation (2.5 life-years gained).
TABLE 2. Utility values before and after lung transplanta-
tion10
0-6 mo 7-18 mo 19-36 mo >36 mo
Before transplantation 0.31
Single-lung transplantation 0.69 0.66 0.65 0.61
Double-lung transplantation 0.75 0.83 0.81 0.82
Heart-lung transplantation 0.67 0.85 0.86 0.87
Figure 2. Breakdown of transplantation costs.
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recipients) are shown in Table 1, as are the extrapolated
survivals to 15 years. On the basis of these data survival
curves were derived, from which survival gains across 15
years were computed (Figure 1). Utility values are shown
in Table 2. The mean expected survival in the medical arm
during the 15-year period was 2.7 years. Relative to this
there were incremental benefits of 2.0, 2.4, and 2.5 life-
years gained with single-lung, double-lung, and heart-lung
transplantation, respectively. Because the quality of life
was better in the single-lung transplantation group, the
incremental QALY gain was greater (2.1 for single-lung
recipients), with double-lung and heart-lung transplanta-
tion giving greater benefit still (3.3 for double-lung recipi-
ents and 3.6 for heart-lung recipients). Nondiscounted
TABLE 3. Mean life-years and QALY per patient through 15 years (discount rate of 6%)
Discounted Nondiscounted
Life-year QALY Life-year gained QALY gained Life-year QALY Life-year gained QALY gained
Medical treatment 2.7 0.8 — — 3.1 1 — —
Single-lung transplantation 4.7 3 2 2.1 6.3 3.9 3.2 3
Double-lung transplantation 5 4.1 2.4 3.3 6.9 5.6 3.8 4.6
Heart-lung transplantation 5.2 4.4 2.5 3.6 7.1 6.1 4.1 5.2
Differences are not exact because of rounding.
TABLE 4. Mean costs incurred through 15 years (discount rate of 6%)
Medical treatment Single-lung transplantation Double-lung transplantation Heart-lung transplantation
UK£ US$ UK£ US$ UK£ US$ UK£ US$
Before transplantation
Conventional care £15,000 $24,600 £15,000 $24,600 £15,000 $24,600
Assessment £2,910 $4,772 £2,910 $4,772 £2,910 $4,772
Transplantation
Donor acquisition £1,444 $2,369 £1,444 $2,369 £1,444 $2,369
Transplant costs £23,198 $38,045 £23,198 $38,045 £23,198 $38,045
Inpatient follow-up £4,645 $7,617 £4,444 $7,289 £5,225 $8,569
Posttransplantation follow-up
Year 1 £15,089 $24,746 £14,818 $24,302 £12,565 $20,607
Year 2 £5,998 $9,836 £5,824 $9,551 £5,536 $9,078
Year 3 £5,550 $9,102 £5,358 $8,788 £5,003 $8,204
Years 4-10 £24,693 $40,497 £26,263 $43,072 £26,382 $43,267
Year 11-15 £9,180 $15,055 £10,818 $17,741 £11,509 $18,875
Medical care alone
Year 1 £12,888 $21,136
Year 2 £9,340 $15,317
Year 3 £6,541 $10,728
Years 4-11 £16,088 $26,384
Total £44,856 $73,564 £107,707 $176,640 £110,078 $180,528 £108,772 $178,387
Totals are not exact because of rounding.
TABLE 5. Cost per life-year gained and QALY gained with lung transplantation across the 15-year period
Benefits discounted Benefits not discounted
Cost per life-year gained Cost per QALY gained Cost per life-year gained Cost per QALY gained
UK£ US$ UK£ US$ UK£ US$ UK£ US$
Single-lung transplantation £30,991 $50,825 £29,415 $48,241 £19,565 $32,086 £21,077 $34,567
Double-lung transplantation £27,678 $45,393 £20,002 $32,803 £17,228 $28,253 £14,076 $23,084
Heart-lung transplantation £25,439 $41,720 £17,856 $29,285 £15,721 $25,782 £12,410 $20,352
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Figure 3. Effect of varying utility value and posttransplantation maintenance cost on cost per QALY estimates for sin-
gle-lung transplantation. Horizontal line defines study cost-utility value of £30,000 per QALY. Diamonds, £250 cost;
squares, £500 cost; triangles, £1000 cost.
TABLE 6. Effects of varying selected factors and assumptions on cost per QALY estimates
Variance in cost per QALY
Single-lung transplantation Double-lung transplantation Heart-lung transplantation
UK£ US$ UK£ US$ UK£ US$
Baseline £29,415 $48,241 £20,002 $32,803 £17,856 $29,285
Increasing cost of transplant operation from £23,000 to £33,000 +£4,588 +$7,524 +£3,006 +$4,930 +£2,739 +$4,491
If maximal survival without transplant is 5 y –£115 –$189 –£117 –$192 +£117 –$192
If posttransplantation survivals are 80%, 50%, 35%, and –£500 –$820 –£419 –$687 +£335 +$549
25% at 1, 5, 10, and 15 y, respectively
Increasing annual cost of medical treatment from –£4,657 –$7,637 –£3,052 –$5,005 –£2,780 –$4,559
£15,000 to £20,000
Increasing mean duration of intensive care admission to 10 d +£2,921 +$4,790 +£1,914 +$3,139 +£1,744 +$2,860
Increasing cost of treating an infection episode from +£1,993 +$3,268 +£1,244 +$2,044 +£804 +$1,318
£2800 to £4000
Assuming new one-off therapy for obliterative £10,000 +£1,582 +$2,594 +£983 +$1,612 +£908 +$1,489
bronchiolitis costing
Assuming monthly maintenance cost increases from +£19,415 +$31,840 +£13,758 +$22,563 +£12,943 +$21,226
£400 to £1200
Varying long-term health utility between 0.4 and 0.9 +£10,892 to +$17,862 to +£13,335 to +$21,869 to +£13,576 to +$22,264 to
–£7,993 –$13,108 –£1,416 –$2,322 –£479 –$786
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benefits are compared with discounted benefits in Table 3.
A substantial proportion of the benefit arising from lung
transplantation occurred in the early posttransplantation
period. Confining the analysis to benefits in the first 5
years yielded QALY gains of 1.1 for single-lung transplan-
tation, 1.6 for double-lung transplantation, and 1.6 for
heart-lung transplantation.
Costs
Summarized costs are shown in Table 4. The mean dis-
counted cumulative costs for 15 years per transplant recipient
were £107,707 ($176,640) for single-lung transplantation,
£110,078 ($180,528) for double-lung transplantation, and
£108,772 ($178,387) for heart-lung transplantation. For the
follow-up period, the mean cost per transplant recipient was
less than the actual maintenance cost per surviving transplant
recipient, because many patients did not survive to incur fol-
low-up costs. The mean cost per transplant fell with each
patient death, with patients who died early having less cost
implication. For example, although the actual cost incurred
by a single-lung transplant recipient in the second year was
£9214 ($15,110), the mean follow-up cost per transplant
recipient in the second year was £5,998 ($9836), because
only 70% of transplant recipients survived into the second
year. Follow-up costs were higher for heart-lung and double-
lung transplantation because of the greater number of sur-
vivors (Table 1). Figure 2 shows the proportions contributed
by the principal sources of cost in the transplant arm. Of the
total cost during the 15-year period, about 40% was related to
costs accrued before or at the time of transplantation.
Cost-Utility
Through 15 years, the incremental costs (relative to medical
treatment) were £62,851 ($103,075) for single-lung trans-
plantation, £65,222 ($106,964) for double-lung transplanta-
tion, and £63,916 ($104,822) for heart-lung transplantation.
The costs per life-year and QALY gained derived from
these figures are shown in Table 5. Single-lung transplanta-
tion was less cost-effective than either double-lung or heart-
lung transplantation, with an incremental cost of about
£10,000 ($16,400) per QALY gained.
Sensitivity Analysis
The cost per QALY estimates were relatively stable with
adjustment of the survival profile and variation of early
posttransplantation assumptions (Table 6). There was, how-
ever, considerable variation in cost utility with changes in
posttransplantation utility weights and follow-up mainte-
nance costs. With variation in utility weight between 0.5
and 0.9, the cost per QALY shifted by about £10,000
($16,400) in all transplantation groups. Figure 3 shows the
interaction between utility weights and maintenance costs
on cost-utility of single-lung transplantation.
Discussion
This study ventured into a relatively understudied area and is
one of few studies that have assessed the cost-effectiveness
of lung transplantation. We found that the costs per QALY
gained by lung transplantation were £29,415 ($48,241) for
single-lung transplantation,, £20,002 ($32,803) for double-
lung transplantation, and £17,856 ($29,285) for heart-lung
transplantation. The cost per QALY estimates were particu-
larly sensitive to changes in utility weightings and follow-up
costs after lung transplantation.
Lung transplantation is a relatively new technology.
Although the first lung transplants in human beings were
reported in 1963,14 it was not until the 1980s that lung trans-
plantation became a feasible and accepted therapeutic tool.15
Both cost and effectiveness data are scarce. There is no
doubt, however, that lung transplantation is an expensive
technology. An early study found the median charge per
heart-lung transplant procedure in 1988 to be $134,881,29
and a later study found a cost per transplant of $153,921.16
A search of the medical literature revealed two previous
studies on the cost-effectiveness of lung transplantation.4,5 A
major strength of our study is that, unlike those two studies,
our analysis was not dependent on data from a single center
but incorporated data from seven centers. These data were
therefore more likely to have included the whole spectrum of
lung disease and to encompass variations in patient charac-
teristics, patient selection, and clinical practice. A multicen-
ter approach also maximized sample size (whereas our study
included survival data from 677 lung transplants, the two
earlier studies4,5 were based on 28 and 57 transplants,
respectively). Our work is also unique in evaluating the cost-
effectiveness of single-lung, double-lung, and heart-lung
transplantation separately, rather than as a single group.
Some limitations were necessarily imposed by the data
and techniques used. First, the use of patients on the waiting
list as a proxy for medical treatment and the assumption that
all these patients are similar both create limitations.17
Unfortunately, suitable control patients are lacking, so
patients on the waiting list remain the group most represen-
tative of medical treatment. Second, our analysis relied
largely on extrapolation of data. Parametric extrapolation
may give a realistic survival profile by allowing gradual
reduction in the hazard rate (patients are increasingly likely
to survive longer after having survived to a given period), it
does not allow for subsequent increases in hazard, for exam-
ple, malignancy and other late complications. An implicit
assumption is that the utility and cost values in the final
epoch measured would persist in the extrapolated study
period. Third, indirect costs were not considered in this
study. Because lung disease is a source of major disability,
there are clear arguments for inclusion of indirect costs, as
was done in the Dutch study.7 Indirect costs, however, are
based on the premise that individuals and their relatives
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return to their productive capacity when the disease has been
relieved,18 and there is evidence that many patients do not
return to work after transplantation.19-22 It would therefore
be a flaw to include costs that assumed restoration of pro-
ductivity after transplantation without some adjustment for
the actual level of productivity. Fourth, we have considered
all patients with lung failure to be a homogeneous group. In
reality, they comprise a heterogeneous group, and costs and
benefits (and thus cost-effectiveness) differ with diagnostic
group, operative risk, and other factors. Small numbers,
however, prevented any meaningful subgroup analysis.
Finally, the difficulty in obtaining reliable UK cost data
meant that costs were not assigned from a single source or
with a single method. Studies on cost-effectiveness of lung
transplantation should be viewed in the context of the rela-
tive infancy and continuing evolution of lung transplanta-
tion, the heterogeneity of patient groups, the lack of
long-term efficacy and cost data, the absence of randomized
trial data, and the infancy of cost-utility work in the area.
This study suggests that lung transplantation does result
in only a small prolongation in life expectancy. Although
the survival gain in this study (from 2.0 to 2.5 years for 15
years) was less than that found in the Dutch study,9 which
yielded a gain of 4.4 years, that study differed in that life-
time benefits were considered. Additionally, although the
survival among patients on the Dutch waiting list5,8 was
similar to that of those in the United Kingdom, the survivals
in the transplantation arm differed, with the Dutch group
reporting a 1-year posttransplantation survival of 86%,
compared with 71% in the United Kingdom, and thus
greater gains in life expectancy. However, the UK survival
data are in line with international registry data23 and are
therefore more reflective of the benefit to be expected from
lung transplantation in most centers. In contrast, Ramsey
and colleagues4 found life expectancies to be similar in
patients undergoing transplantation and those on the wait-
ing list, which suggests that lung transplantation might not
confer a significant survival benefit for all recipients, an
assertion later supported by analysis of United Network for
Organ Sharing (UNOS) registry data.24
Because of differences in health care systems, costs, and
funding, economic data cannot be directly generalized or
extrapolated across international boundaries, which is why it
is important to perform economic studies in different coun-
tries. The cost per QALY found in this study is less than the
estimates from the Dutch group ($71,200)9 and from
Ramsey and colleagues in the United States ($176,817).4
Economic evaluation of other transplanted organs in the
United States and The Netherlands has estimated costs per
QALY gained of between $35,000 and $40,000 for heart
transplantation30 and $38,000 for liver transplantation.25
Ramsey and colleagues’ data4 came from a pilot US
study and thus represented a small sample from an initial
experience. Because the data were North American, the
costs of health care would invariably be higher than in the
United Kingdom. The main difference between the Dutch
and UK data were in the follow-up costs: monthly costs per
patient in the third year were £880 ($1443) in the United
Kingdom and £1255 ($2058)in the Dutch study. Sensitivity
analysis in our study showed that cost-utility was notably
sensitive to monthly follow-up values. If the UK monthly
maintenance cost rose to £1255, the cost per QALY for sin-
gle-lung transplantation would be $77,000. Although the
survival profiles in the UK and Dutch cohorts differed, the
cost per QALY gained was not sensitive to changing sur-
vival profiles. The follow-up costs used in this study were
based on data from a single UK unit. It is possible that this
unit’s management routine differs from management else-
where. Small variations in management can have major cost
implications; for example, Ramsey and colleagues4 used an
extended regimen of ganciclovir prophylaxis for
cytomegalovirus pneumonia, with a single course costing
more than $20,000. Another major difference between the
UK and Dutch studies was in pretransplantation costs,
which averaged £18,000 and £30,000, respectively. The
higher pretransplantation cost in the Netherlands may be
due in part to the low acceptance rate (only 10% of all
referred patients are accepted for transplantation),26
because substantial costs are accrued by patients who are
assessed but not accepted for transplantation. If the pre-
transplantation costs in this study were the same as in The
Netherlands, the cost per QALY gained would increase by
about £4000 ($6560).
Implications
Health care spending on lung transplantation in all countries
is currently limited by the availability of donors, and this
donor scarcity effectively limits the cost burden of lung trans-
plantation. Although this cost-utility study helps by providing
some quantitative economic data on lung transplantation,
these data unlikely to have any major implications for general
health resource allocation. If xenografts or artificial lungs
were to become a clinical reality, however, cost-effectiveness
data would assume vital importance, because the limit to the
number of transplants performed would depend largely on
the funds available to lung transplantation.
The main implications of the data presented in this arti-
cle are related to decision making within lung transplanta-
tion. One major controversy is the choice of procedure:
double-lung versus heart-lung transplantation and single-
lung versus double-lung transplantation. The data from this
study suggest that double-lung and heart-lung transplanta-
tion are similar in efficacy and cost-effectiveness, but the
same cannot be said for single-lung transplantation. This
study adds cost-effectiveness to the arguments favoring the
use of double-lung as opposed to single-lung transplanta-
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tion. The debate on how best to use the limited supply of
donor lungs is not straightforward,27,28 however, and is not
limited to efficacy and cost-effectiveness. Single-lung trans-
plantation allows more members of society to benefit from
transplantation, although at the expense of a poorer quality
of life. From an economic viewpoint, the additional societal
benefit of single-lung transplantation cannot be neglected
and has not been accounted for in this analysis.
Finally, data from economic evaluations are helpful in
determining the cost implications of management changes
with respect to the overall cost and cost-effectiveness of lung
transplantation. For example, one could determine the impact
of introducing new management tools (such as a costlier
immunosuppressive drug), changes in practice (such as
change in listing criteria), or increased availability of donors
(such as in xenotransplantation). Incremental cost-effective-
ness of several clinical options can thus be determined, pro-
viding economic data to guide management decisions.
Lung transplantation is an effective but expensive tech-
nology relative to conventional medical treatment. Cost-
effectiveness is not an intrinsic characteristic of a
technology but depends on how it is applied.1 It remains
desirable to discriminate those patients and circumstances
for which single-lung, double-lung, or heart-lung transplan-
tation presents a reasonably cost-effective use of resources,
thus allowing efficient use of the limited resources available
for both transplantation and general health care provision.
As long-term data become available, further studies will
define these relationships more precisely.
We thank the UK Cardiothoracic Transplant Audit Steering
Group for granting us access to UK outcome data.
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Discussion
Dr Bryan F. Meyers (St Louis, Mo). There is clear evidence
that because of the high costs of medical care and the infinite
capacity of the medical community to spend money on innovative,
high-cost, and high-tech medical therapies, we will increasingly
be called on to justify the benefits gained for each unit of expen-
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diture we make. Work such as this study is essential to the devel-
opment of our ability to accurately assign relative values to thera-
pies for diverse medical conditions.
Anyanwu and colleagues are to be commended for the metic-
ulous preparation of this article. Its strengths include the involve-
ment of multiple transplant centers, the large number of patients
studied, and the care with which the statistical and economic
analyses were conducted. To perform such an analysis, one is
forced to make multiple assumptions. I personally disagree with
many of the assumptions that they made, but much of my dis-
agreement comes from differences in the lung transplantation sit-
uation between the United Kingdom and the United States. Our
costs for both surgical and medical therapy are much higher, our
waiting lists are much longer, and, as a result, our patients are
listed earlier in their physiologic decline. As a result, many of the
assumptions used for this article would not hold true for our trans-
plant programs. Regardless, this article is a valuable contribution
and raises the bar for cost-utility analyses in the field of lung
transplantation.
For my first question, can you defend the decision to assign a
constant utility or quality of life value to patients on the waiting
list? It is clearly acknowledged that pulmonary failure is a pro-
gressive process. Patients’ conditions deteriorate while they are on
the waiting list, and many die or are withdrawn from consideration
because of this deterioration. Clearly their measured quality of life
must also decline, and your failure to capture this decline dimin-
ishes the measured benefit of transplantation.
Second, why did you stratify your analysis on the type of trans-
plant, rather than on other variables that are much more important
in determining outcomes? Hosenpud and colleagues in 1998
showed us that when transplantation was compared with medical
therapy, lung transplantation decreased mortality risks for patients
with cystic fibrosis and idiopathic pulmonary fibrosis, but the mor-
tality risk of lung transplant recipients with emphysema remained
higher than that faced by their counterparts on the waiting list for
at least the first year after transplantation. Isn’t it possible that
recipient diagnosis is exerting a hidden influence in your results,
because patients with cystic fibrosis, who are younger and who
arguably derive the greatest survival and utility benefit, all get
double-lung transplants or heart-lung transplants in your system?
Finally, shouldn’t these cost-utility estimates be immediately
accompanied by some calculation of the error associated with the
estimate, such as SD or 95% confidence interval? Your abstract
and your article give the strong impression that heart-lung trans-
plantation is most cost-effective, followed by double-lung trans-
plantation and then by single-lung transplantation. This perception
is created by reporting only the seemingly precise point estimates
of cost per QALY gained. Although your sensitivity analysis is
thorough, it is provided late in the article, and it strikes me as anal-
ogous to placing a startling headline on the front page of a news-
paper and burying the tempering details somewhere in the inner
pages. Can we reliably conclude that the cost-utilities for the three
procedures are statistically different?
Dr Tom Waddell (Toronto, Ontario, Canada). The Cambridge
group has just recently published an economic analysis of lung
transplantation looking at long-term immunosuppression and the
different regimens that are potentially available, and mycopheno-
late mofetil in particular came out poorly as an expensive option.
What chronic maintenance immunosuppression was used in your
economic assumptions?
Dr Abdelghany Mohamed Abdelghany (Cairo, Egypt). As
for me, it is difficult to compare a life-saving procedure with other
medications and other procedures, because lung transplantation is
a life-saving procedure for idiopathic pulmonary hypertension in a
child. I also want to know how double-lung transplantation is less
costly than double-lung transplantation with heart transplantation?
Dr David J. Sugarbaker (Boston, Mass). In your extended life
table analysis of survival, you predicated the survival after 15 years
on the results of the first 4 years. In light of the aggressive nature
of bronchiolitis obliterans and the prediction from some groups that
if the patient lives long enough, he or she will indeed die of chronic
rejection, is that a valid way of calculating extended survival?
Dr Anyanwu. I’ll start with the last question. It has to do with
extrapolation. As I said, that is a deficiency of any economic study.
Bronchiolitis obliterans is not the only thing that can come into
play. There is also the issue of neoplasia. The assumption is that
the hazards that persist in the first 4 years will continue to decline
at the same rate. Unfortunately, every economic study has to make
assumptions, and there is no way around this until we have defin-
itive, reliable long-term data. So we had no other way other than
to make that extrapolation, but the observation is valid.
With respect to the issue of transplanting two lungs as opposed
to one as more cost-effective, I think there are enough data. For
example, data from Bavaria and colleagues* and a lot of other
workers suggest that transplanting two lungs is physiologically
more beneficial than transplanting one lung, and certainly in the
United Kingdom we have found the same to be the case in terms
of both survival and quality of life.
As regards comparing a life-saving procedure with other pro-
cedures, whether we like it or not, we live in the real world. To you
spending, say, £1 million to save a life might seem to be the right
thing to do; somebody with arthritis might rather have £50,000
pounds spent for a hip replacement. We live in the real world and
compete for resources, not only with health care sectors but with
non–health care sectors.
Long-term immunosuppression was based on a cyclosporine-
based triple-therapy regimen with azathioprine, and the long-term
follow-up costs were based on data from the Cambridge group.13
With respect to the assumption of constant utility for patients
on the waiting list, several assumptions were made because the
numbers are small. We had considered dividing this group into
diagnostic subgroups, but this would have led to even smaller
numbers, and the resulting estimates would be more unstable. The
simplifying assumption was necessary because of the small num-
bers in our study.
We stratified according to the type of transplant. Because part
of the debate in lung transplantation is on the type of transplanta-
tion that is preferable: single-lung transplantation, double-lung
transplantation, or heart-lung transplantation. Another reason is
that because there is much practice variation in the United
Kingdom, we thought it would be inappropriate to group all three.
It is true that, for example, patients with cystic fibrosis would
benefit more, and this probably contributes to the picture of heart-
*Bavaria JE, Kotloff R, Palevsky H, Rosengard B, Roberts JR, Wahl PM,
et al. Bilateral versus single lung transplantation for chronic obstructive
pulmonary disease. J Thorac Cardiovasc Surg. 1997;113:520-7.
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lung transplantation as the most cost-effective, because in the
United Kingdom this procedure is used primarily for cystic fibro-
sis. However, I must say that in the Dutch study, in which they
grouped all three transplantation types together, their findings
were quite similar to ours. As more data emerge, it would be use-
ful to consider emphysema, pulmonary fibrosis, and cystic fibrosis
separately, and this would be something that we would look into.
With respect to imprecision of measurement and error rates, the
problem is that a cost-utility estimate is based on two separate sta-
tistics, the cost and the utility, which are combined. Although we
can, for example, get confidence limits for the costs and for the
benefits, it is difficult to combine the two to come up with an error
measurement for a cost-utility estimate, and how to do this
remains a matter of disagreement among economists and statisti-
cians. Because of this lack of agreement, we have not done that.
As I said, however, with sensitivity analysis the assumptions are
fairly robust.
Finally, as regards the other question whether the cost-utilities
were statistically different between the groups: I did not in any
way suggest that heart-lung and double-lung transplantation are
different. I think that they are fairly the same. The fact that there
was a difference of $1000 or $2000 is neither here nor there. To
see the difference with single-lung transplantation does not really
need statistical testing, however, because the survival is poorer and
the quality of life is also poorer, so by definition the cost would be
much higher for each unit of benefit.
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